Mechanistic trials are needed to evaluate whether GLP-1 receptor agonists can correct the potential metabolic imbalance between increased renal energy expenditure and impaired substrate metabolism proposed to underlie DKD. The gene discussed is GLP1R; the disease is diabetic kidney disease.